Lourdes Mendez, MD, PhD

Assistant Professor

DownloadHi-Res Photo

Are You a Patient?

View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.

View Doctor Profile

Contact Info

lourdes.mendez@yale.edu

About

Titles

Assistant Professor

Biography

Dr. Lourdes Mendez received her medical degree from Albert Einstein College of Medicine, as well as a PhD in Cell Biology. She completed her residency at Weill Cornell-New York Presbyterian and while a fellow in hematology/oncology at BIDMC, undertook a post-doctoral fellowship in cancer genetics. Most recently, Dr. Mendez was an Instructor of Medicine at Harvard Medical School and the Leukemia Disease Group Leader at BIDMC. She is currently a member of the Yale Leukemia Clinical and Research Team with a focus on clinical care and trials for patients with acute lymphoblastic leukemia. Dr. Mendez is dedicated to both the clinical care of patients and translational research with the goal of translating findings from the bench to the bedside to improve outcomes for patients with high-risk acute leukemia and precursor conditions (CHIP/CCUS).

Appointments

Medical Oncology and Hematology
Assistant Professor
Primary

Education & Training

Research Fellow: Beth Israel Deaconess Medical Center (2017)

Clinical Fellow in Hematology/Oncology: Beth Israel Deaconess Medical Center (2014)

Resident: Weill Cornell-New York Presbyterian (2011)

Intern: Weill Cornell-New York Presbyterian (2009)

PhD: Albert Einstein College of Medicine, Cell Biology

MD: Albert Einstein College of Medicine

Research

Overview

Dr. Mendez is dedicated to both the clinical care of patients with myeloid disorders/leukemia, and translational research to identify novel therapeutics for these conditions.

Medical Research Interests

Leukemia, Myeloid

Research at a Glance

Yale Co-Authors

Frequent collaborators of Lourdes Mendez's published research.

Amer Zeidan, MBBS
View Full Profile
View 2 Common Publications
Jennifer VanOudenhove, PhD
View Full Profile
View Common Publication
Natalia Neparidze, MD
View Full Profile
View Common Publication
Nikolai Podoltsev, MD, PhD
View Full Profile
View Common Publication
Rong Wang, PhD
View Full Profile
View Common Publication
Rory Shallis, MD
View Full Profile
View Common Publication

Publications

2023

Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence
Shallis R, Wang R, Zeidan A, Huntington S, Neparidze N, Stempel J, Mendez L, Di M, Ma X, Podoltsev N. Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence. Blood Advances 2023, 7: 3213-3224. PMID: 36939371, PMCID: PMC10338212, DOI: 10.1182/bloodadvances.2022009074.
Peer-Reviewed Original Research
MeSH Keywords and Concepts
Clonal Hematopoiesis: Origins and determinants of evolution.
Mendez LM, Patnaik MM. Clonal Hematopoiesis: Origins and determinants of evolution. Leuk Res 2023, 129: 107076. PMID: 37075557, DOI: 10.1016/j.leukres.2023.107076.
Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms
Xie Z, Chen E, Mendez L, Komrokji R, Zeidan A. Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms. The Cancer Journal 2023, 29: 130-137. PMID: 37195768, DOI: 10.1097/ppo.0000000000000656.
Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
MeSH Keywords and Concepts
Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings.
Garcia JS, Flamand Y, Penter L, Keng M, Tomlinson BK, Mendez LM, Koller P, Cullen N, Arihara Y, Pfaff K, Wolff JO, Brunner AM, Galinsky I, Bashey A, Antin JH, Cutler C, Ho V, Jonas BA, Luskin MR, Wadleigh M, Winer ES, Savell A, Leonard R, Robertson T, Davids MS, Streicher H, Rodig SJ, Ritz J, Wu CJ, DeAngelo DJ, Neuberg D, Stone RM, Soiffer RJ. Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings. Blood 2023, 141: 1884-1888. PMID: 36332187, DOI: 10.1182/blood.2022017686.
Peer-Reviewed Original Research

2022

Is it the time to integrate novel sequencing technologies into clinical practice?
VanOudenhove J, Halene S, Mendez L. Is it the time to integrate novel sequencing technologies into clinical practice? Current Opinion In Hematology 2022, 30: 70-77. PMID: 36602939, DOI: 10.1097/moh.0000000000000754.
Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
MeSH Keywords and Concepts

2021

Circulating Protein Disulfide Isomerase Is Associated with Increased Risk of Thrombosis in JAK2-Mutated Myeloproliferative Neoplasms.
Sharda AV, Bogue T, Barr A, Mendez LM, Flaumenhaft R, Zwicker JI. Circulating Protein Disulfide Isomerase Is Associated with Increased Risk of Thrombosis in JAK2-Mutated Myeloproliferative Neoplasms. Clin Cancer Res 2021, 27: 5708-5717. PMID: 34400417, DOI: 10.1158/1078-0432.CCR-21-1140.
Peer-Reviewed Original Research

2020

VWF maturation and release are controlled by 2 regulators of Weibel-Palade body biogenesis: exocyst and BLOC-2.
Sharda AV, Barr AM, Harrison JA, Wilkie AR, Fang C, Mendez LM, Ghiran IC, Italiano JE, Flaumenhaft R. VWF maturation and release are controlled by 2 regulators of Weibel-Palade body biogenesis: exocyst and BLOC-2. Blood 2020, 136: 2824-2837. PMID: 32614949, DOI: 10.1182/blood.2020005300.
Peer-Reviewed Original Research

2019

Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial
Brunner A, Blonquist T, DeAngelo D, McMasters M, Fell G, Hermance N, Winer E, Lindsley R, Hobbs G, Amrein P, Hock H, Steensma D, Garcia J, Luskin M, Stone R, Ballen K, Rosenblatt J, Avigan D, Nahas M, Mendez L, McAfee S, Moran J, Bergeron M, Foster J, Bertoli C, Manning A, McGregor K, Fishman K, Kuo F, Baltay M, Macrae M, Burke M, Behnan T, Wey M, Som T, Ramos A, Rae J, Lombardi Story J, Nelson N, Logan E, Connolly C, Neuberg D, Chen Y, Graubert T, Fathi A. Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. The Lancet Haematology 2019, 7: e122-e133. PMID: 31837959, DOI: 10.1016/s2352-3026(19)30203-0.
Peer-Reviewed Original Research
MeSH Keywords and Concepts
The Interplay Between the Genetic and Immune Landscapes of AML: Mechanisms and Implications for Risk Stratification and Therapy.
Mendez LM, Posey RR, Pandolfi PP. The Interplay Between the Genetic and Immune Landscapes of AML: Mechanisms and Implications for Risk Stratification and Therapy. Front Oncol 2019, 9: 1162. PMID: 31781488, DOI: 10.3389/fonc.2019.01162.
Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
Germline NPM1 mutations lead to altered rRNA 2'-O-methylation and cause dyskeratosis congenita.
Nachmani D, Bothmer AH, Grisendi S, Mele A, Bothmer D, Lee JD, Monteleone E, Cheng K, Zhang Y, Bester AC, Guzzetti A, Mitchell CA, Mendez LM, Pozdnyakova O, Sportoletti P, Martelli MP, Vulliamy TJ, Safra M, Schwartz S, Luzzatto L, Bluteau O, Soulier J, Darnell RB, Falini B, Dokal I, Ito K, Clohessy JG, Pandolfi PP. Germline NPM1 mutations lead to altered rRNA 2'-O-methylation and cause dyskeratosis congenita. Nat Genet 2019, 51: 1518-1529. PMID: 31570891, DOI: 10.1038/s41588-019-0502-z.
Peer-Reviewed Original Research

See All Publications

Clinical Trials

Current Trials

Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia
HIC ID2000035900RoleSub InvestigatorPrimary Completion Date08/31/2026
Recruiting Participants
Leukemia
Phase I/II Open-Label Study to Assess Safety, Tolerability and Preliminary Efficacy of the CLEVER-1 Antibody Bexmarilimab in Combination With Azacitidine or Azacitidine/Venetoclax in Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia or Acute Myeloid Leukemia
HIC ID2000034403RoleSub InvestigatorPrimary Completion Date12/31/2024
Recruiting Participants
Leukemia
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate-Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-Naive Participants Who Are Non-Transfusion Dependent (NTD): The "ELEMENT-MDS" Trial
HIC ID2000035577RoleSub InvestigatorPrimary Completion Date06/25/2027
Recruiting Participants
Leukemia
A Phase 1/2 First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
HIC ID2000034410RoleSub InvestigatorPrimary Completion Date06/01/2025
Recruiting Participants
Leukemia
A Phase 1/2 Open Label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
HIC ID2000032345RoleSub InvestigatorPrimary Completion Date02/29/2024
Recruiting Participants
Leukemia

See All Current Clinical Trials

Academic Achievements & Community Involvement

activity
American Society of Hematology
Professional OrganizationsMember
Details

Clinical Care

Overview

Lourdes Mendez, MD, PhD, is a hematologic oncologist specializing in the treatment of leukemia, particularly acute lymphoblastic leukemia.

As an assistant professor at Yale School of Medicine, Dr. Mendez is involved in research that seeks to develop new therapeutic options for leukemia and myeloid disorders (a group of blood cancers that affect the bone marrow’s ability to produce healthy blood cells). Her research aims to translate laboratory findings into clinical applications to enhance patient care.

Dr. Mendez received her medical training from Albert Einstein College of Medicine and completed her residency at Weill Cornell-New York Presbyterian. She pursued a fellowship in hematology and oncology at Beth Israel Deaconess Medical Center, where she also completed a postdoctoral fellowship in cancer genetics.

Hematology; Hematologic Oncology

Fact Sheets

Acute Myeloid Leukemia (AML)
Learn More on Yale Medicine
Diagnosing Leukemia
Learn More on Yale Medicine
Cytogenic Studies for Leukemia Diagnosis
Learn More on Yale Medicine
Leukemia in Children
Learn More on Yale Medicine

See All Fact Sheets On Yale Medicine

Yale Medicine News

February 27, 2017
How Apheresis Helps Battle Autoimmune Disease
Research & InnovationRead on Yale Medicine

View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.

View Doctor Profile

News

Get In Touch

Contacts

lourdes.mendez@yale.edu

Appointment Number

203.200.4363

Locations

Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
See Patient Care Locations

Are You a Patient?

Contact Info

Titles

Biography

Appointments

Medical Oncology and Hematology

Other Departments & Organizations

Education & Training

Overview

Medical Research Interests

Research at a Glance

Yale Co-Authors

Amer Zeidan, MBBS

Jennifer VanOudenhove, PhD

Natalia Neparidze, MD

Nikolai Podoltsev, MD, PhD

Rong Wang, PhD

Rory Shallis, MD

Publications

2023

2022

2021

2020

2019

Clinical Trials

Current Trials

American Society of Hematology

Overview

Clinical Specialties

Fact Sheets

Acute Myeloid Leukemia (AML)

Diagnosing Leukemia

Cytogenic Studies for Leukemia Diagnosis

Leukemia in Children

Yale Medicine News

How Apheresis Helps Battle Autoimmune Disease

Are You a Patient?

News

Yale’s Post ASH Review: Highlights from the 2024 American Society of Hematology Annual Meeting

Yale’s Post ASH Review

Dr. Lourdes Mendez on Yale Cancer Answers

Yale Hematology Welcomes Two Hematologists

Contacts

Locations

Patient Care Locations